DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 37+ companies and 40+ pipeline drugs in EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in EGFR Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ EGFR Non-Small Cell Lung Cancer Pipeline Outlook
Key Takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report
Stay informed about the cutting-edge advancements in EGFR Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ EGFR Non-Small Cell Lung Cancer Clinical Trials Assessment
EGFR Non-Small Cell Lung Cancer Emerging Drugs Profile
Zipalertinib is a next-generation oral, irreversible, small molecule designed to target EGFR activating mutations, including EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR. The FDA granted breakthrough therapy designation to zipalertinib for the treatment of patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations and who have received prior platinum-based chemotherapy. The drug is currently being evaluated under Phase III clinical studies for the treatment of non-small cell lung cancer.
BBT-176 is a novel epidermal growth factor receptor – tyrosine kinase inhibitor (EGFR-TKI), which is designed to inhibit EGFR with C797S mutations, which arise as Tagrisso (osimertinib) resistant mutations following Tagrisso treatment in non-small cell lung cancer (NSCLC). In the pre-clinical studies, BBT-176 exhibited strong anti-tumor efficacy in C797S triple mutations. The drug is in the Phase I/II stage of development for the treatment of non-small-cell lung cancer.
ORIC-114 is a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, making it a promising therapeutic candidate to address the unmet medical need of having both meaningful systemic as well as CNS antitumor activity. It is currently being evaluated under Phase I clinical study for the treatment of non-small-cell lung cancer.
Learn more about EGFR Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking EGFR Non-Small Cell Lung Cancer Research and development projects @ EGFR Non-Small Cell Lung Cancer Unmet Needs
EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
Discover the latest advancements in EGFR Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ EGFR Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives
EGFR Non-Small Cell Lung Cancer Companies and Drugs
Scope of the EGFR Non-Small Cell Lung Cancer Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of EGFR Non-Small Cell Lung Cancer Pipeline on our website @ EGFR Non-Small Cell Lung Cancer Drugs and Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/